Call for Papers: Pollution and Epigenetics
Guest Editors: Wim Vanden Berghe (University of Antwerp in Belgium, Lifestyle Epigenetics Editor) and Steven Gray (St James University in Ireland, Nutritional Epigenetics Editor)
In 2013, it was reported that an eight-year-old girl developed lung cancer [Kessler, R. (2014) Nature. 509(7502):S62-3.]. The cause of her cancer was attributed by her doctor to be due to accumulation of fine particulate matter in her lungs leading to neoplastic change. From diesel particulates to endocrine disruptors, asbestos, heavy metals to molecules like bisphenol A (BPA), it is becoming increasingly clear that man’s propensity to pollute has significant consequences on human health. Moreover, strong evidence now links such pollution to changes within our epigenomes. In this thematic series, we explore the causes and consequences of pollution on the epigenome, how this may have effects not only on the epigenetics of the individual exposed to such pollution, but also review how this may be further exacerbated by downstream or “transgenerational” inheritance of these epigenetic changes. With the recent world-wide concerns regarding “micro-plastics”, should we be concerned that nano-technology could further expose our epigenomes to additional environmental challenges?
In a series of cutting-edge reviews Clinical Epigenetics will explore these possibilities in a thematic series on “Pollution and Epigenetics,” reviewing the critical roles that exposure to environmental pollution may have on the epigenome.
Deadline for submissions: December 15, 2018
Pluripotent Stem Cells
First published: 19 July 2018
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016
Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015
Aims & Scope
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms. The journal is divided into the following sections:
- Aging and development epigenetics
- Allergy, immunology, and pathogen epigenetics
- Cancer epigenetics and diagnostics
- Cardiovascular epigenetics
- Endocrinology and metabolic epigenetics
- Environmental epigenetics
- Epigenetic Biomarkers
- Epigenetic Technologies
- Epigenetic drugs and clinical trials
- Innovative therapies
- Lifestyle epigenetics
- Neurology and psychiatry epigenetics
- Regenerative Medicine
- Reproductive and Transgenerational Epigenetics
For more information on the the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.
Graphical Abstracts Now Available
Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript. An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.
Systems Epigenetics: Towards Precision Medicine Cancer Conference
November 27-30, 2018 in Amsterdam, The Netherlands at the KIT Royal Tropical Institute
Learn more about the meeting here.
From the blog
In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.
- Editorial Board
- Sign up for article alerts and news from this journal
2017 Journal Metrics
67.9 days to first decision for reviewed manuscripts only
59.8 days to first decision for all manuscripts
131.0 days from submission to acceptance
15.8 days from acceptance to publication
598 Altmetric mentions